Drug Utilisation of Mysimba/Contrave
Launched by CURRAX PHARMACEUTICALS · Oct 17, 2023
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • At least one prescription of Mysimba/Contrave in his/her medical records any time during the study period (US) OR at least one dispensing of Mysimba/Contrave in his/her registry any time during the study period (Nordic);
- • At least 365 days of computerized records prior to first Mysimba/Contrave prescription or dispensing date; and3Patient is active (i.e., alive and registered/accruing data) at the time of the first Mysimba/Contrave prescription or dispensing date.
- Exclusion Criteria:
- • - All patients meeting inclusion criteria will be included in the study; no exclusion criteria will be applied.
About Currax Pharmaceuticals
Currax Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies that address unmet medical needs in the fields of pain management and neurological disorders. With a focus on advancing patient care through scientific rigor and clinical excellence, Currax harnesses cutting-edge research to bring new treatment options to market. The company prioritizes collaboration with healthcare professionals and stakeholders to ensure its products effectively enhance the quality of life for patients. Through its commitment to integrity and innovation, Currax Pharmaceuticals aims to be a leader in transforming therapeutic approaches and improving health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nashville, Tennessee, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported